...
首页> 外文期刊>Scientific reports. >CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes
【24h】

CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes

机译:CRISPR工程化的镶嵌技术迅速揭示了小鼠 Kcnj13 功能的丧失模仿了人类疾病的表型

获取原文
           

摘要

The era of genomics has demanded the development of more efficient and timesaving approaches to validate gene function in disease. Here, we utilized the CRISPR-Cas9 system to generate Kcnj13 mutant mice by zygote injection to verify the pathogenic role of human KCNJ13 , mutations of which are thought to cause Leber congenital amaurosis (LCA), an early-onset form of blindness. We found that complete loss of Kcnj13 is likely postnatal lethal. Among surviving F0-generation mice examined, 80% show mosaic KCNJ13 expression in the retinal pigment epithelium (RPE). Mosaic expression correlates with decreased response to light and photoreceptor degeneration, indicating that Kcnj13 mutant mice mimic human KCNJ13 -related LCA disease. Importantly, mosaic animals enable us to directly compare Kcnj13 mutant and wild-type RPE cells in the same eye. We found that RPE cells lacking KCNJ13 protein still survive but overlying photoreceptors exhibit cell degeneration. At the same time, wild-type RPE cells can rescue neighboring photoreceptor cells that overlie mutant RPE cells. These results suggest that KCNJ13 expression is required for RPE cells to maintain photoreceptor survival. Moreover, we show that CRISPR-Cas9 engineered mosaicism can be used to rapidly test candidate gene function in vivo .
机译:基因组学时代要求开发更有效,更省时的方法来验证疾病中的基因功能。在这里,我们利用CRISPR-Cas9系统通过合子注射产生Kcnj13突变小鼠,以验证人类KCNJ13的致病作用,认为其突变会导致Leber先天性黑眼症(LCA),这是一种早期发病的失明形式。我们发现,Kcnj13的完全丧失可能是产后致命的。在存活的F0代小鼠中,有80%在视网膜色素上皮(RPE)中显示镶嵌KCNJ13表达。马赛克表达与对光和光感受器变性的降低的反应相关,表明Kcnj13突变小鼠模仿了人类KCNJ13相关的LCA疾病。重要的是,镶嵌动物使我们能够在同一只眼中直接比较Kcnj13突变型和野生型RPE细胞。我们发现缺少KCNJ13蛋白的RPE细胞仍然可以存活,但是上层的感光细胞表现出细胞变性。同时,野生型RPE细胞可以拯救覆盖突变RPE细胞的邻近感光细胞。这些结果表明RPE细胞需要KCNJ13表达来维持感光细胞的存活。此外,我们显示CRISPR-Cas9工程化的镶嵌技术可用于在体内快速测试候选基因功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号